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To the Editor: Allen and colleagues2 provided an in-depth review of 
the pathophysiology and functional outcomes of diabetic 
polyneuropathy (DPN) among patients with diabetes mellitus (DM). As 
explained,2 DPN often manifests in a symmetrical and length-
dependent pattern affecting distal portions of long peripheral nerves of 
patients with DM,11 Here we highlight the molecular pathogenesis 
within the soma of the motoneuron, which may also inform clinical 
treatment. Although DPN manifests in neuronal axons, the deleterious 
molecular cascade begins within the soma of the peripheral nerve 
located within the anterior horn of the spinal cord. Glucose is 
transported into the milieu of nervous tissue independent of insulin,5 
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which results in a hyperglycemic metabolic milieu of nervous system 
tissue in patients with DM. Excessive glucose is metabolized into 
sorbitol and fructose, and both activate advanced glycation end 
products (AGEs), resulting in molecular oxidative stress.3 Oxidative 
stress within the soma triggers withdrawal of the longest (typically 
most distal) nerve axons from their distal terminals without cellular 
death.12 This observation is clinically relevant, because there is the 
potential for recovery from structural damage to the axon before death 
of the nerve soma.9 The precise mechanism by which oxidative stress 
triggers distal axonal retraction is unclear but likely involves disruption 
of sodium-potassium pump activity (Na+/K+-ATPase)10 and 
downregulation of insulin-like growth factor 1 (IGF-1),8 leading to 
disruption of the neuromuscular junction. Consequently, denervation 
of distal muscle fibers occurs and the soma signals lateral sprouting of 
the retracted distal axon to innervate more proximal muscle fibers.4 
The net result is a loss of motor unit numbers,12 an increase in the size 
of surviving motor units,12 and subsequent reduction of maximal 
muscle force1 and control of muscle force. 
The distinction between the pathogenesis beginning within the 
neuronal axon or soma could have important implications for clinical 
interventions. For example, the nerve soma could be targeted with 
interventions (e.g., pharmacological) to preserve the function of the 
neuron. Clinically, the most sensitive tools identified to date for 
assessing DPN-related impairments of neuromuscular function 
(compared with DM patients without DPN) are isometric strength of 
distal muscles (e.g., plantar and dorsiflexors)1,6 and the timed up and 
go (TUG) test.7 Thus the molecular underpinnings of DPN are likely 
related to the functional outcomes discussed by Allen and colleagues,2 
and further understanding the involved mechanisms may help guide 
clinical practice. 
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